What is Unchained Labs?
Founded in 2014 and headquartered in Pleasanton, California, Unchained Labs is a specialized developer of high-performance analytical tools designed to solve complex challenges in biologics and gene therapy research. The company distinguishes itself through its proprietary platforms, such as the Optim system, which serves as a multiplex protein stability solution. By streamlining the workflows of researchers, Unchained Labs addresses critical bottlenecks in drug discovery and development, positioning itself as an essential partner for pharmaceutical and biotechnology organizations worldwide. Its market position is characterized by a commitment to innovation that directly impacts the efficiency and reliability of real-world scientific experimentation.
How much funding has Unchained Labs raised?
Unchained Labs has raised a total of $285M across 6 funding rounds:
Series A
$25M
Series B
$25M
Series C
$13M
Series D
$17M
Unspecified
$50M
Debt
$155M
Series A (2015): $25M with participation from Canaan Partners, TPG Biotech, and Novo Ventures
Series B (2016): $25M led by Canaan Partners, TPG Biotech, and Novo Ventures
Series C (2017): $13M supported by TPG Biotech, Canaan Partners, and Novo Ventures
Series D (2018): $17M featuring TPG Biotech, Canaan Partners, and Novo Ventures
Unspecified (2019): $50M backed by Silicon Valley Bank
Debt (2021): $155M with participation from MidCap Financial and Golub Capital
Key Investors in Unchained Labs
Canaan Partners
Canaan is an early-stage venture capital firm that invests in technology and healthcare companies, backing founders from seed through growth stages in areas such as enterprise software, fintech, consumer, biopharma, and digital health.
TPG Biotech
TPG is a global alternative asset management firm founded in 1992 with investment strategies spanning private equity, growth equity, impact investing, real estate, market solutions and credit.
Novo Ventures
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, focusing on long-term value creation in the life sciences sector.
What's next for Unchained Labs?
With the recent strategic investment of $155M, Unchained Labs is well-positioned to accelerate its product roadmap and expand its global footprint. The company is expected to leverage this capital to enhance its R&D capabilities, potentially diversifying its portfolio of analytical instruments to address emerging needs in the gene therapy space. As the firm continues to scale, the focus will likely shift toward optimizing operational efficiencies and deepening its penetration into key international markets. By maintaining its focus on high-value, problem-tackling technology, Unchained Labs remains a prime candidate for sustained long-term growth and potential market consolidation within the life sciences instrumentation sector.
See full Unchained Labs company page
